Globus Medical Stock (NYSE:GMED), Trade Ideas

Globus Medical

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.

News

Markets

Trading Ideas

GMED

Globus Medical (NYSE: GMED) continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company is expanding in the overseas markets through the expansion of direct and distributor sales force.

Globus Medical (GMED) Gains From New Launches Amid Macro Issues

Analyst Color

Equities

Upgrades

Price Target

Analyst Ratings

General

Stifel analyst Mathew Blackman upgraded Globus Medical, Inc. (NYSE: GMED) to Buy from Hold,

Globus Medical&#39;s Untapped Potential Beyond The NUVA Transaction; Analyst Turns Bullish

Minimally Invasive Surgery — This Company’s Successful Trial Could Help Eliminate The Need For An Incision In Patients With Back Pain

Biotech

Penny Stocks

ISRG

NMTC

As medical technology progresses, the world’s approach to surgical operations is also advancing and changing significantly. As part of this, minimally invasive surgery (MIS), in recent years, has taken the forefront of the surgical industry, and there are no surprises why.

Minimally Invasive Surgery — This Company&#39;s Successful Trial Could Help Eliminate The Need For An Incision In Patients With Back Pain

Globus Medical, Inc. Class A Common Stock

Globus Medical Inc

<p>In an exclusive&nbsp;interview, <strong>Christine Smith</strong>, founder and CEO of&nbsp;<a href="https://eatgron.com/"><strong>Gr&ouml;n Edibles</strong></a>, provided an in-depth look at the economic dynamics of operating a cannabis edibles brand across various states.</p>
<p>2024 marks a significant year for Gr&ouml;n, with expansion into multiple U.S. markets including New York, New Jersey,<a href="https://www.benzinga.com/topic/ohio-cannabis"> Ohio</a>&nbsp;and <a href="https://www.benzinga.com/topic/maryland-cannabis">Maryland</a>, enhancing their presence to a total of eight U.S. and Canadian markets.</p>
<h3>Strategic Expansion And Market Dynamics</h3>
<p>Smith emphasized the strategic selection of states based on detailed market analysis. &quot;Each state is very different,&quot; <a href="https://www.benzinga.com/markets/cannabis/24/03/37945428/how-to-spot-and-seize-market-opportunities-with-products-you-love-top-cannabis-brand-founder-has">Smith</a> noted, highlighting the unique regulatory and market environments that influence their expansion strategy. For instance, Ohio&#39;s recent shift to adult use and its limited license model presents a promising market, similar to past <a href="https://www.benzinga.com/markets/cannabis/24/04/38078767/exclusive-missouris-cannabis-market-sees-surge-with-high-dose-products">successes in Missouri</a>.</p>
<p>While less structured, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36250035/a-2024-investor-guide-to-new-yorks-cannabis-market-expansion-the-mso-wealth-roadmap">New York offers vast potential</a> due to its focus on brand scalability. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33329222/the-maryland-effect-a-game-changer-for-the-east-coast-cannabis-industry">Maryland</a>, often overlooked, was chosen based on robust data analytics, including retailer and license counts, and market share opportunities, making it a strategic part of Gr&ouml;n&#39;s East Coast presence.</p>
<h3>Supply Chain Complexity And Ingredient Sourcing: Adapting to Localized Manufacturing Needs</h3>
<p>Gr&ouml;n&#39;s commitment to organic, single-origin ingredients and fair-trade certified suppliers, is a cornerstone of its market appeal, yet this approach presents considerable challenges in navigating the fragmented regulatory landscape of the U.S. cannabis market.</p>
<p>In states like Ohio, regulations prohibit the purchase of oil on the open market, necessitating that companies process oil only within the licensed facilities. To manage these challenges, Gr&ouml;n has diversified its sourcing strategy to ensure a steady supply of biomass, crucial for scalable operations as it enters new markets.</p>
<p>Smith noted the strategic importance of biomass availability: &quot;We will not enter a market if we don&#39;t know that we have the biomass and availability to be able to move at scale.&quot;</p>
<p>Further complicating their operations, Gr&ouml;n has adopted a unique manufacturing model to comply with varied state laws. &quot;We set up our kitchens in all of our facilities. We operate under a <a href="https://www.benzinga.com/markets/cannabis/23/11/35662129/are-traditional-cannabis-licensing-models-obsolete-how-reverse-licensing-can-help">reverse licensing model</a>,&quot; Smith described. In this model, Gr&ouml;n builds up a production space to their specifications under someone else&#39;s license, approved by the state.</p>
<p>This setup involves using their equipment, such as water-jacketed kettles for cooking gummies and tempering <a href="https://www.benzinga.com/markets/cannabis/23/02/31079080/if-you-like-chocolate-youll-love-gr-n-cannabis-edibles-made-by-an-architect-turned-confectioner">machines for chocolate</a>, making it &quot;much less of a kitchen and far more of a production manufacturing facility.&quot;</p>
<p>The need to tailor production processes to each state&#39;s regulations prevents the streamlining of operations across the board. In Canada, for instance, where Gr&ouml;n can operate nationally, the setup is significantly different and more efficient compared to the U.S., where they must establish separate facilities in each state.</p>
<p>&quot;The equipment we&#39;re using in Canada, which is national, allows us to do one facility for the entire country, is very different than what we&#39;re doing here in the States,&quot; Smith added, highlighting the extensive manual labor involved due to each state&#39;s distinct rules.</p>
<h3>Technology And Operational Efficiency</h3>
<p>For Gr&ouml;n, leveraging technology and innovative manufacturing processes is essential in <a href="https://www.benzinga.com/general/biotech/23/08/33579692/cannabis-robots-meet-the-company-boosting-efficiency-and-margins-through-packaging-automation">optimizing production costs</a> and ensuring <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/09/34625368/nasa-precision-meets-cannabis-roi-pre-rolled-infusion-robots-revolutionizing-indust">consistent product quality</a> across a wide range of markets.</p>
<p>Smith explained that this lack of uniformity leads to a reliance on both manual labor and automated systems, tailored to each location. Gr&ouml;n&rsquo;s operations require using smaller, more versatile equipment that can be adjusted to meet local requirements, thereby maintaining compliance while still striving for efficiency.</p>
<p>Moreover, Gr&ouml;n&#39;s approach to technology not only involves the physical machinery but also extends to their<a href="https://www.benzinga.com/general/biotech/23/02/30915385/exclusive-how-to-lower-the-cost-of-cannabis-quality-and-save-30-of-your-top-line-revenue"> software systems</a>, which must be flexible enough to handle varied regulatory demands from tracking and reporting to quality control.</p>
<h3>Product Development And Consumer Engagement: Adapting to Local Markets</h3>
<p>Gr&ouml;n&#39;s product development is deeply influenced by consumer trends, requiring a strategic balance between innovation and economic viability.</p>
<p>With over 250 SKUs tailored to meet the diverse regulatory and consumer landscapes of various states, Gr&ouml;n&#39;s approach to <a href="https://www.benzinga.com/news/23/04/32018716/exclusive-what-it-takes-to-build-a-successful-cannabis-edibles-brand-a-discussion-with-industry-lead">product creation and marketing</a> is meticulously localized.</p>
<p>Smith elaborates on the complexities involved in adapting product formulations to suit different markets, particularly when it comes to the use of <a href="https://www.benzinga.com/markets/cannabis/20/08/17023053/cannabis-concentrates-a-beginners-guide-1">cannabis extracts</a> like<a href="https://www.benzinga.com/markets/cannabis/24/03/37850817/vaping-emerges-as-a-preferred-method-for-rosin-consumption-in-cannabis-market"> rosin and distillate</a>.</p>
<p>&quot;We&#39;re using rosin depending on the market, and that&#39;s the thing because every market has a different availability as the markets mature,&quot; Smith explained. For example, in the West Coast markets like Oregon, there is a large and consistent availability of rosin, which allows for its broader use in products.</p>
<p>However, in other regions, the limited availability of such extracts requires Gr&ouml;n to adjust their formulations to include a blend of rosin and distillate based on what is locally accessible.</p>
<h3>Pricing Across Markets</h3>
<p>This variability in ingredient availability not only affects the type of products that can be offered in different states but also impacts Gr&ouml;n&#39;s pricing strategy. &quot;In Oregon, we can get oil for $1.50 a gram. On the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38282615/cannabis-brands-leading-market-expansion-in-east-midwest-a-look-at-prices-and-trend"> East Coast</a>, we&#39;re looking at oil for $15 a gram, sometimes $20 a gram,&quot; Smith noted, highlighting the significant cost differences that can affect product pricing and margins.</p>
<p>Despite these challenges, Gr&ouml;n is committed to maintaining a consistent quality and price point for consumers, which occasionally means absorbing higher costs in markets where inputs are more expensive.</p>
<p>The strategy involves a long-term view where initial sacrifices in margins are seen as an investment in establishing market presence and consumer trust. &quot;We sacrifice the margins on the front end for the longevity of having consistency and pricing,&quot; Smith added.</p>
<p>This approach is crucial for <a href="https://www.benzinga.com/news/24/03/37944162/is-the-future-of-the-marijuana-industry-shaped-by-consumer-packaged-goods-or-vice-versa">consumer packaged goods (CPG)</a> like those offered by Gr&ouml;n, where consumer expectations around product quality and price consistency are high.</p>
<p>Smith is optimistic about the future, focusing on minor cannabinoids and new product developments like low-dose sleep aids, reflecting Gr&ouml;n&#39;s commitment to innovation aligned with consumer needs.</p>
<p>&quot;We are 100% committed to <a href="https://www.benzinga.com/general/biotech/23/10/35300227/from-cbn-cbg-to-thcv-consumer-centric-brands-embrace-rare-cannabinoids-for-differentiation">minor cannabinoids</a>. They play a significant role in our product effects and formulations. Hopefully, we&#39;ll see clearer regulations from federal authorities soon,&rdquo; Smith said.</p>
<p>&ldquo;As for our investments in minor cannabinoids, we&#39;re <a href="https://www.benzinga.com/news/events/24/04/38185665/surge-in-missouris-cannabis-sales-spurs-new-product-launch-by-gr-n">doubling down</a>. We&#39;re excited about our upcoming product release in May&mdash;it&#39;s a super sleep aid featuring a 10 to 1 ratio, with 25mg of CBN and 2.5mg of THC. It&#39;s designed for consumers who prefer a lower dose than a full 10mg gummy. We&rsquo;re also exploring THC-V and sugar-free options, among other minor cannabinoids,&quot; Smith noted.</p>
<p><em>Photo: AI-Generated Image.&nbsp;</em></p>


Cannabis

Government

Regulations

Emerging Markets

Entrepreneurship

Retail Sales

Management

Success Stories

Exclusives

Interview

Inside Grön's Marijuana Edibles Factory: What Can We Learn About Choco-Nomics And Multi-State Expansion?

<h3 class="wp-block-heading"><strong>Congresswoman Advocates for Marijuana Banking Reform</strong></h3>
<p>In a bid to advance cannabis legislation, Congresswoman <strong>Maxine Waters</strong> (D- CA) champions the need for marijuana<a href="https://www.benzinga.com/markets/cannabis/24/04/38416745/three-pathways-to-federal-cannabis-legalization-that-investors-are-watching-closely"> banking reform,</a> highlighting bipartisan collaboration. Waters, a ranking member of the House Financial Services Committee, stresses the urgency of passing the <a href="https://www.benzinga.com/topic/safe-banking-act">Secure and Fair Enforcement Regulation </a>(SAFER) Banking Act, <a href="https://www.marijuanamoment.net/key-congresswoman-says-now-is-the-time-to-pass-marijuana-banking-bill-despite-mcconnells-concerns/">reported </a>Marijuana Moment. This legislation aims to provide banking services to cannabis businesses, addressing their current lack of access to traditional financial institutions due to federal prohibition.</p>
<p>Despite potential challenges from Senate Minority Leader <strong>Mitch McConnell</strong>, Waters expresses optimism and determination to overcome obstacles. </p>
<p>"I know that there may be some concerns with McConnell, but I am hopeful that we can overcome that (&#8230;), we've got to have SAFER Banking, and most of us who have been working on this support that." </p>
<h3 class="wp-block-heading"><strong>Washington State Proposes Diversity Measures For Cannabis Ownership</strong></h3>
<p>The <a href="https://www.benzinga.com/markets/cannabis/23/02/30902464/washington-state-liquor-and-cannabis-officials-face-obstacles-to-personal-use-under-federal-laws">Washington State Liquor and Cannabis Board (WSLCB)</a> introduces amendments to foster diversity in cannabis ownership. With a focus on inclusivity, the proposed changes aim to encourage minority participation and eliminate licensing barriers in cannabis retail. Acknowledging the importance of equitable access, the WSLCB seeks to create a more inclusive landscape.</p>
<p>The WSLCB members<a href="https://tvw.org/video/washington-state-liquor-and-cannabis-board-2024041034/?eventID=2024041034"> received a briefing</a> on proposed changes to the scoring criteria for minority license applicants, aiming to prioritize those most affected by the war on drugs. One proposed change involves considering convictions for all drugs, not just marijuana, in the scoring process. These revisions to the scoring system reflect feedback from social equity applicants in the initial round of applications.</p>
<h3 class="wp-block-heading"><strong>New Hampshire Senate Reviews Marijuana Legalization Bill</strong></h3>
<p>A New Hampshire bill legalizing marijuana, passed by the House, now faces scrutiny in a Senate committee. Opponents, including state Sen. <strong>Daryl Abbas</strong> (R) and Senate president <strong>Jeb Bradley</strong> (R), propose significant modifications.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Senate Judiciary (04/25/2024)" width="500" height="281" src="https://www.youtube.com/embed/qQHRZsEvhcQ?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p><figcaption class="wp-element-caption">Senate Judiciary Session of 04/25/2024</figcaption></p></figure></p>
<p>Earlier this year, the House-approved <a href="https://legiscan.com/NH/bill/HB1633/2024">HB 1633</a> permits 15 statewide retail stores, imposing a 10% state charge on adult-use purchases. Medical marijuana remains tax-exempt and regulated under an &#8220;agency store&#8221; model with strict marketing limitations.</p>
<p>Abbas&#8217;s proposed changes aim to elevate penalties for<a href="https://www.benzinga.com/markets/cannabis/24/04/38326268/cannabis-consumption-legal-or-not-in-your-state-everyone-seems-to-be-consuming-at-equal-rates-ne"> public consumption</a>, turning repeat offenses into misdemeanors with potential jail time, contradicting legalization goals. Additionally, Abbas&#8217;s amendment suggests a shift to a franchise system, overseen by the state&#8217;s Liquor Commission, governing the aesthetics and operations of the 15 stores. This, among other amendments, might distort the original spirit of HB1633, putting it at risk of failing in the House when revised, proponents of the bill alerted. </p>


Push For Cannabis Banking Reform, Washington Social Equity, New Hampshire Debates Retail Weed Sales And More

<p>With the potential legalization of adult-use marijuana under Amendment 3, Florida&#39;s cannabis market is set for a significant transformation. <a href="https://www.benzinga.com/topic/florida-cannabis">Florida&#39;s legal cannabis</a> spending is projected to grow at a 12% CAGR from 2023 to 2028, with total sales expected to reach $4.5 billion by 2028, positioning Florida as the second-largest U.S. cannabis market after California.</p>
<h3>Competitive Landscape And Consumer Behavior</h3>
<p>Florida&#39;s retail cannabis landscape has already shown significant growth, with the number of dispensaries rising to 628 by April 2024, as per&nbsp;<a href="https://www.benzinga.com/topic/bdsa"><strong>BDSA</strong></a> data.&nbsp;</p>
<p>The state&#39;s medical cannabis sector remains robust, with patient numbers surpassing 878,000 this month and sales reaching $2.6 billion in 2023, marking an 18% increase from the previous year.</p>
<p>As Florida prepares for a November ballot initiative on adult-use legalization, BDSA analyst <strong>Brendan Mitchel-Chesebro</strong> underscores the legislative uncertainty around <a href="https://www.benzinga.com/markets/cannabis/24/04/38299011/its-on-the-ballot-the-future-of-adult-use-cannabis-in-florida-whats-the-contingency-plan-if-lega">Amendment 3</a>, which allows but does not require the expansion of adult-use cannabis licenses.</p>
<p>This leaves the future market landscape uncertain. If the initiative passes, BDSA forecasts sales of $874 million in 2025 for the adult-use segment.</p>
<p>In this context, existing operators like <a href="https://www.benzinga.com/markets/cannabis/24/04/38313915/cannabis-in-florida-the-bellamy-brothers-tell-trulieve-ceo-we-rolled-a-fat-one-when-legalization">Trulieve</a> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/tcnnf#OTC">TCNNF</a>) are advised to refine their strategies to cater to a potentially larger and more diverse consumer base.</p>
<p>As consumer penetration rates are expected to surge&mdash;mirroring trends observed in other states transitioning to adult use&mdash;companies must adeptly navigate evolving preferences across different product forms and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37666783/marijuana-shoppers-favorite-strains-2024">usage motivations</a> to maintain or enhance their market shares.</p>
<p>Mitchel-Chesebro points out that, unlike other adult-use markets, only 31% of Florida consumers currently prioritize <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38341510/how-to-max-profits-this-420-smart-discounts-amid-sales-spike-of-premium-marijuana">low-cost</a>, compared to 36% in general adult-use markets.</p>
<p>However, the typical initial price increase following legalization might heighten price sensitivity among <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38037571/floridas-6b-cannabis-market-anticipates-400-growth-following-court-decision-allowin">Florida shoppers</a>.</p>
<p>This, along with the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36268367/u-s-cannabis-market-premium-products">growing popularity of infused pre-rolls</a> and a notable 47% year-over-year growth in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33369455/sweet-treats-take-over-gummie-consumption-outpaces-flower-in-latest-consumer-data-h">edibles sales</a>, indicates significant upcoming shifts in consumer behavior as the market expands.</p>
<h3>Strategies For Market Entry And Expansion</h3>
<p>As the Florida market braces for a likely uptick in mergers and acquisitions, Mitchel-Chesebro advises new entrants and expanding firms to adopt a nuanced pricing strategy.</p>
<p>Using BDSA&rsquo;s Price Tiers analysis, he highlights the potential for brands to capitalize on specific product segments where premium offerings are underrepresented relative to their market performance.</p>
<p>For example, in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35991290/analyst-inside-look-trends-and-opportunities-in-ohios-emerging-recreational-cannabi">markets like Ohio</a>, premium-priced flower products disproportionately contribute to sales relative to their market availability. Identifying and targeting these lucrative price tiers can be a key strategy for newly introduced brands aiming for rapid growth in new markets.</p>
<p><em>Photo: AI-Generated Image.&nbsp;</em></p>


Market Summary

TCNNF

Landing In Florida's Cannabis Market: Legal Adult-Use Marijuana Could Yield $874M In 2025

<h3 class="wp-block-heading"><strong>Health Recall: Microbial Contamination Alert In British Columbia</strong></h3>
<p>In an uncommon event,<strong> <a href="https://recalls-rappels.canada.ca/en/alert-recall/sirona-pharma-inc-acreage-pharms-ltd-recalls-one-lot-full-sesh-purple-gelato-punch">Health Canada </a></strong><a href="https://recalls-rappels.canada.ca/en/alert-recall/sirona-pharma-inc-acreage-pharms-ltd-recalls-one-lot-full-sesh-purple-gelato-punch">recalls Sirona Pharma Inc.&#8217;s Full Sesh Purple Gelato Punch</a> dried cannabis sold in British Columbia due to microbial contamination. The recall responds to a quality control measure.</p>
<p><a href="https://www.benzinga.com/markets/cannabis/23/09/34548455/medical-cannabis-in-canada-faces-decline-whats-behind-the-38-drop-in-registrations">Health Canada&#8217;s </a>Cannabis Data Gathering Program identified microbial contaminant levels exceeding specified limits, potentially posing health risks. While no adverse health reports have been received, consumers have been alerted and are advised to cease using the recalled product immediately. With 1200 units sold between September 18, 2023, and April 18, 2024, the product must be returned to retailers or disposed of safely. Further specification on the contaminant was not made public. </p>
<h3 class="wp-block-heading"><strong>Manitoba&#8217;s Home Cultivation Ban Reversal: Shifting Regulations</strong></h3>
<p>Manitoba&#8217;s political landscape is undergoing a significant shift as the <a href="https://winnipeg.citynews.ca/2024/04/19/manitoba-set-to-remove-provinces-ban-on-growing-cannabis/">provincial government plans to overturn its ban on homegrown cannabis cultivation</a>. Aligned with federal law and evolving societal attitudes, this reversal reflects changing political dynamics and public sentiment regarding cannabis regulations.</p>
<p>The decision comes as Manitoba and Quebec were the only provinces to enforce restrictions against growing adult-use marijuana at home following <a href="https://www.benzinga.com/topic/canada-cannabis">Canada&#8217;s </a>legalization of recreational cannabis in 2018. With the <strong>New Democratic Party of Manitoba (NDP) </strong>now in power, the province anticipates lifting the ban, marking a pivotal moment in cannabis policy reform.</p>
<h3 class="wp-block-heading"><strong>International Expansion: Greenway Greenhouse Cannabis Corporation Receives Certifications</strong></h3>
<p>In other news, <a href="https://www.benzinga.com/markets/cannabis/23/09/34951623/greenway-greenhouse-cannabis-launches-first-brands-in-the-canadian-market">Greenway Greenhouse</a> Cannabis Corporation (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GWAY#CSE">GWAY</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/GWAYF#OTCQB">GWAYF</a>) <a href="https://www.prnewswire.com/news-releases/greenway-receives-international-cannabis-accreditation-302128092.html">announced </a>a significant milestone as its cultivation facility in Leamington, Ontario receives CUMS-GAP and GACP certification. This achievement positions Greenway to distribute its high-quality greenhouse cannabis internationally, tapping into new markets and revenue streams.</p>
<p>The certifications, completed through Control Union, demonstrate compliance with strict international standards, allowing Greenway to engage with multiple international cannabis purchasers. With an annual cultivation capacity of 24,000 kg, Greenway aims to capitalize on the export market&#8217;s potential, enhancing revenue, gross margins, and global presence.</p>
<p>&#8220;Receiving these certifications opens up a whole new world of opportunities for Greenway,&#8221; said <strong>Jamie D&#8217;Alimonte</strong>, CEO of Greenway. &#8220;With our most recent expansion, we are able to scale up production to meet any new demand for our product internationally.&#8221;</p>
<p>As Canada&#8217;s cannabis industry continues to evolve, these developments signal both challenges and opportunities for stakeholders, shaping the future of cannabis regulation, consumer safety and market expansion.</p>


Media

CSE:GWAY

GWAYF

Canada Cannabis Update: Health Recall, Home Cultivation Ban Reversal, International Expansion

<p>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 5 years by 5.0% on an annualized basis producing an average annual return of 16.57%. Currently, IDEXX Laboratories has a market capitalization of $41.47 billion. </p>
<p><strong>Buying $1000 In IDXX:</strong> If an investor had bought $1000 of IDXX stock 5 years ago, it would be worth <strong>$2,164.47</strong> today based on a price of $499.30 for IDXX at the time of writing.</p>
<h3>IDEXX Laboratories's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714167027_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


IDXX

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today

<p>Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) has outperformed the market over the past 10 years by 13.17% on an annualized basis producing an average annual return of 23.61%. Currently, Progressive has a market capitalization of $121.84 billion. </p>
<p><strong>Buying $1000 In PGR:</strong> If an investor had bought $1000 of PGR stock 10 years ago, it would be worth <strong>$8,578.56</strong> today based on a price of $208.03 for PGR at the time of writing.</p>
<h3>Progressive's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714167022_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In This Stock 10 Years Ago Would Be Worth $8,600 Today

<p>During the last three months, 4 analysts shared their evaluations of Bread Finl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Bread Finl Hldgs, presenting an average target of $34.75, a high estimate of $48.00, and a low estimate of $26.00. Surpassing the previous average price target of $30.33, the current average has increased by 14.57%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714165300_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Bread Finl Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$33.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Bill Carcache</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$32.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bread Finl Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bread Finl Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Bread Finl Hldgs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bread Finl Hldgs's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BFH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bread Finl Hldgs analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Bread Finl Hldgs</h2>
<p>Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains minority interest in its recently spun-off LoyaltyOne division, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.</p>
<h3>Financial Milestones: Bread Finl Hldgs's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Bread Finl Hldgs's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-1.55%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> Bread Finl Hldgs's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>4.23%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Bread Finl Hldgs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>1.49%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.19%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Bread Finl Hldgs's debt-to-equity ratio is below the industry average at <strong>1.86</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 4 Analyst Insights On Bread Finl Hldgs

<p>In the preceding three months, 4 analysts have released ratings for Reliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $360.5, a high estimate of $380.00, and a low estimate of $345.00. This upward trend is apparent, with the current average reflecting a 17.24% increase from the previous average price target of $307.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714165265_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Reliance. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$345.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Daniel Knauff</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Katja Jancic</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$355.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Philip Gibbs</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$362.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Reliance. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Reliance compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Reliance's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Reliance analyst ratings.</strong></a></p>
<h2>About Reliance</h2>
<p>Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.</p>
<h3>Understanding the Numbers: Reliance's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Reliance's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately <strong>-7.57%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Reliance's net margin excels beyond industry benchmarks, reaching <strong>8.17%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Reliance's ROE excels beyond industry benchmarks, reaching <strong>3.53%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Reliance's ROA excels beyond industry benchmarks, reaching <strong>2.6%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Reliance's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.18</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Forecasting The Future: 4 Analyst Projections For Reliance

<p>Analysts' ratings for VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated VF and provided 12-month price targets. The average target is $16.38, accompanied by a high estimate of $22.00 and a low estimate of $12.00. A 9.25% drop is evident in the current average compared to the previous average price target of $18.05. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714165258_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive VF. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Laurent Vasilescu</td>
<td>Exane BNP Paribas</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.50</td>
<td>$15.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$22.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to VF. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of VF compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of VF's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of VF's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VFC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on VF analyst ratings.</strong></a></p>
<h2>Get to Know VF Better</h2>
<p>VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.</p>
<h3>Unraveling the Financial Story of VF</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> VF's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately <strong>-16.16%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> VF's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-1.43%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> VF's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-1.97%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> VF's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.33%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> VF's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>3.48</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


12 Analysts Assess VF: What You Need To Know

<p>Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) has outperformed the market over the past 15 years by 3.58% on an annualized basis producing an average annual return of 15.74%. Currently, Eagle Materials has a market capitalization of $8.84 billion. </p>
<p><strong>Buying $100 In EXP:</strong> If an investor had bought $100 of EXP stock 15 years ago, it would be worth <strong>$921.72</strong> today based on a price of $256.70 for EXP at the time of writing.</p>
<h3>Eagle Materials's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714165230_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $100 In This Stock 15 Years Ago, You Would Have $900 Today

<p>Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 4.87% on an annualized basis producing an average annual return of 15.31%. Currently, Apollo Global Management has a market capitalization of $63.76 billion. </p>
<p><strong>Buying $100 In APO:</strong> If an investor had bought $100 of APO stock 10 years ago, it would be worth <strong>$413.64</strong> today based on a price of $112.22 for APO at the time of writing.</p>
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714165225_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

<p>Ratings for Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $24.57, a high estimate of $32.00, and a low estimate of $18.00. This current average reflects an increase of 22.85% from the previous average price target of $20.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714165216_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of Vital Farms's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ben Klieve</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$19.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brian Holland</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Ben Klieve</td>
<td>Lake Street</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Matthew Smith</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Adam Samuelson</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vital Farms. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vital Farms compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Vital Farms's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Vital Farms's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VITL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Vital Farms analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Vital Farms</h2>
<p>Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter &amp; Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).</p>
<h3>Vital Farms: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Vital Farms showcased positive performance, achieving a revenue growth rate of <strong>23.37%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>5.31%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Vital Farms's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.84%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Vital Farms's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.75%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.12</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VITL

Breaking Down Vital Farms: 7 Analysts Share Their Views

<p><a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38327580/exclusive-kind-founders-reveal-how-theyre-building-a-better-web3-for-creators-gamers-and-c"><strong>Kind</strong></a>, the innovative Web3 creators agency known for enhancing the digital experiences of creators and gamers, recently hosted one of the largest online parties in Web 3 history.&nbsp;This <a href="http://www.benzinga.com/markets/cryptocurrency/24/02/37252915/exclusive-pixels-web3-gaming-revolution-luke-barwikowski-tells-all">monumental event on </a><strong><a href="http://www.benzinga.com/markets/cryptocurrency/24/02/37252915/exclusive-pixels-web3-gaming-revolution-luke-barwikowski-tells-all">Pixels</a> </strong>attracted up to 126,000 players, witnessed by over 2,500 viewers on Twitch, and connected more than 100 key opinion leaders (KOLs) simultaneously.</p>
<blockquote class="twitter-tweet"><p>126K USERS SHOWED UP TO THE <a href="https://twitter.com/Kind_HQ?ref_src=twsrc%5Etfw">@Kind_HQ</a> ENERGY PARTY LETS GOOOOOO</p>
<p>&mdash; heidi (@heidichristne) <a href="https://twitter.com/heidichristne/status/1781350014046101662?ref_src=twsrc%5Etfw">April 19, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><p><em>See also:<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38327580/exclusive-kind-founders-reveal-how-theyre-building-a-better-web3-for-creators-gamers-and-c">&nbsp;Kind Founders Reveal How They&#39;re Building A Better Web3 For Creators, Gamers And Communities</a></em></p>
<p>The party wasn&#39;t just about breaking records; it was a showcase of community and technology. Attendees enjoyed a slew of rewards, including Pixels tokens, TEK Guild memberships, and VIP in-game passes, enhancing their interactive experience.</p>
<p>This event marks a significant milestone in the Web3 community, demonstrating Kind&rsquo;s commitment to building a more engaging and rewarding platform for creators and gamers alike. As Web3 continues to evolve, Kind is at the forefront, pushing the boundaries of what&#39;s possible in virtual spaces.</p>
<p><em>See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37252915/exclusive-pixels-web3-gaming-revolution-luke-barwikowski-tells-all" target="_blank">EXCLUSIVE: Pixels&#39; Web3 Gaming Revolution - Luke Barwikowski Tells All</a></em></p>
<p>In the aftermath of their successful event, Kind took to X to express heartfelt thanks to everyone who played a pivotal role in the organization and execution of their massive online party in Pixels. They extended their gratitude to <a href="https://x.com/kyleblohm?s=21">Kyle Blohm</a> for his expertise in crafting the event, and to Heidi Christne for her pivotal role in making the event possible. Appreciation was also shown to <a href="https://x.com/chief_axiegg?s=21">Chief</a>&nbsp;for an enthralling Twitch stream, and to partners like TEK and <a href="https://twitter.com/TriballyGames">Tribally Games</a> for their significant contributions to the event&#39;s success in the Pixels ecosystem. Additionally, Kind acknowledged <a href="https://x.com/e4e_gg?s=21">Esports4Everyone</a>, Sourbeck, and Covetor for their exceptional efforts in stream production, which peaked at over 2,700 viewers on Twitch.</p>
<blockquote class="twitter-tweet"><p>126000 Players attended the <a href="https://twitter.com/pixels_online?ref_src=twsrc%5Etfw">@pixels_online</a> Kind Energy Party!</p>
<p>We are grateful to the community for the support and to Pixels for the opportunity to do this Event that represented a Milestone in KIND&#39;s History.</p>
<p>Thank you very much to the architect of the event <a href="https://twitter.com/KyleBlohm?ref_src=twsrc%5Etfw">@KyleBlohm</a>,&hellip; <a href="https://t.co/1NsrcaBeVL">https://t.co/1NsrcaBeVL</a> <a href="https://t.co/ib9Bat3jOl">pic.twitter.com/ib9Bat3jOl</a></p>
<p>&mdash; KIND (@Kind_HQ) <a href="https://twitter.com/Kind_HQ/status/1781480503121444880?ref_src=twsrc%5Etfw">April 20, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Gaming

$PIXEL

Kind Hosts Massive 126K-Attendee Web3 Online Party In Pixels

<p>The National Highway Traffic Safety Administration (NHTSA) has initiated a new investigation into <strong>Tesla Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)&#8217;s handling of a December recall that affected 2 million vehicles that are equipped <a href="https://www.benzinga.com/topic/tesla-autopilot">with the Autopilot software.</a></p>
<p>The recall involves all Tesla models, including Model Y, X, S, 3, and Cybertruck, and was intended to enact additional safeguards on the Autopilot system following a <a href="https://www.benzinga.com/government/23/12/36255070/teslas-autopilot-recall-what-went-wrong-with-the-self-driving-dream">series of concerning crashes. </a></p>
<p>Yet with the NHTSA receiving reports of 20 crashes involving the vehicles post-update, the effectiveness of these measures is now under review, Reuters reported Friday. </p>
<p>The new investigation adds to the regulatory scrutiny of Autopilot at a time when CEO <strong>Elon Musk </strong>is pushing for full self- driving, as Tesla is offering a month of free trials and plans to unveil <a href="https://www.benzinga.com/news/24/04/38396288/teslas-robotaxi-to-be-called-cybercab-elon-musk-says-self-driving-fleet-will-be-like-combination-of">its Robotaxi on Aug. 8.</a></p>
<h4 class="wp-block-heading">Regulatory Focus On Autopilot&#8217;s Safety Record</h4>
<p>The latest NHTSA report highlights that despite the recall, new incidents involving Autopilot have surfaced, including several crashes. </p>
<p>The regulator&#8217;s Office of Defects Investigation has noted these occurrences and has performed preliminary tests on vehicles that received the updated software.</p>
<p>The ongoing safety evaluation highlights a significant disconnect between user expectations of Autopilot's capabilities and its actual functionality, according to the regulatory agency. This &#8220;critical safety gap&#8221; has reportedly led to misuse by drivers, resulting in avoidable accidents. </p>
<p>The agency criticized Tesla for using the term &#8220;Autopilot,&#8221; suggesting it &#8220;may lead drivers to believe that the automation has greater capabilities than it does and invite drivers to overly trust the automation.&#8221;</p>
<p>NHTSA&#8217;s findings suggest the updated Autopilot software still allows users to revert to previous settings, potentially undermining safety enhancements.<br /><br />Tesla did not respond to a request for comment from Reuters, the news agency reported. </p>
<p>In its report, the NHTSA said Tesla&#8217;s approach to Autopilot functionality is markedly different from other auto manufacturers. </p>
<h4 class="wp-block-heading">Concerns Over Data Gaps, Crash Reporting</h4>
<p>NHTSA has also raised concerns regarding the completeness of Tesla&#8217;s crash data reporting. </p>
<p>The agency pointed out that Tesla's data collection primarily captures incidents where airbags are deployed, representing a fraction of all Autopilot-related crashes. </p>
<p>This creates a substantial gap in understanding the full extent of issues associated with Autopilot use, the agency said. </p>
<h4 class="wp-block-heading">Calls For Stricter Regulation</h4>
<p>This renewed probe by NHTSA is part of a series of investigations by various government agencies into Tesla&#8217;s Autopilot. </p>
<p>The Justice Department and the Securities and Exchange Commission are also examining claims that Tesla may have misled consumers and investors about the capabilities of Autopilot, potentially overstating its effectiveness.</p>
<p><strong>Market Reactions</strong></p>
<p>Tesla shares dropped by 1.7% on Friday, yet they have climbed more than 13.7% over the week, representing the strongest weekly gain for the stock in almost a year.</p>
<p>Read now: <em><a href="https://www.benzinga.com/news/earnings/earnings-beats/24/04/38467013/tech-stocks-rebound-as-magnificent-7-roar-on-strong-earnings-energy-giants-tumble-wh">Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What&#8217;s Driving Markets Friday?</a></em></p>
<p><em>Photo courtesy of Tesla. </em></p>


Large Cap

Tech

TSLA

Auto Watchdog Intensifies Probe Into Tesla's Autopilot Recall As Safety Concerns Mount

<p><strong>James M. Fejes Jr.</strong>, owner of <strong>Flying High Investments LLC</strong>, faces the loss of his pilot license after <a href="https://www.benzinga.com/topic/cannabis-legalization">transporting cannabis within Alaska</a>. </p>
<p>The Federal Aviation Administration (FAA) revoked his certificate despite Fejes&#8217;s argument that since cannabis is legal in Alaska, its transportation should be legal as well.</p>
<p>The trouble began when the FAA discovered that Fejes was using his private plane for cannabis distribution following a report from the state&#8217;s Alcohol and Marijuana Control Office. </p>
<p>For starters, Fejes allegedly violated tracking requirements. While cultivation facilities must adhere to strict protocols, known as seed-to-sale tracking, Fejes misrepresented his transport methods, triggering the investigation.</p>
<p>Alaska, which has a land area of&nbsp;570,865.8 square miles&nbsp;and a water area of 94,722.2 square miles, is the largest US state by area. Small planes are essential for transporting supplies, food and people to hard-to-reach places across Alaska.</p>
<h2 class="wp-block-heading">Pilot&#8217;s Appeal Falls On Deaf Ears</h2>
<p>Fejes appealed to multiple bodies, including an administrative law judge and the National Transportation Safety Board, but was unsuccessful. His final appeal to the 9th Circuit challenged the FAA&#8217;s jurisdiction, arguing the transportation occurred solely within the state of Alaska. However, the court disagreed, asserting that Congress&#8217;s authority over interstate commerce extends to airspace regulation.</p>
<p>Fejes also claimed that because Alaska hadn't convicted him of any wrongdoing, the FAA had no right to revoke his license based on punishable actions. The 9th Circuit rejected Fejes&#8217;s arguments of misinterpreted law and overstepped authority and upheld the FAA&#8217;s decision.</p>
<p>The three-judge panel found that the Alaska law legalizing marijuana distribution did not override federal law that criminalizes the action.</p>
<p>"Although many states have legalized recreational marijuana, it continues to be a controlled substance federally," wrote Judge Ryan D. Nelson, one of the judges on the 9th Circuit, <a href="https://www.adn.com/alaska-news/crime-courts/2024/04/25/pilot-cant-fly-marijuana-to-retail-stores-in-alaska-even-if-sales-are-legal-federal-judges-rule/">reported</a> Anchorage Daily News.</p>
<h2 class="wp-block-heading">It Could Be Worse</h2>
<p>Even though the U.S. Department of Justice has directed prosecutors to exercise discretion in pursuing certain marijuana crimes in states where pot is legal, the opinion that "does not alter marijuana's status — it remains illegal under federal law."</p>
<p>The court opinion also ruled that even if Fejes' plane was only used within the state, it is considered an interstate form of transportation.</p>
<p>"Even if an airplane, like a car, is mainly used for intrastate activities, its operations could substantially impact interstate commerce," the panel found.</p>
<p>The FAA&#8217;s actions indicate a strict stance against such offenses, suggesting possible legal consequences for Fejes beyond having his license revoked. As a federal crime, distributing marijuana via aircraft, whether Fejes meant to break the law or not, could carry a sentence of at least one year.</p>
<p><em>Photo courtesy of Fly Around Alaska Flight School</em></p>
<p><em>Now Read: <a href="https://www.benzinga.com/short-sellers/24/04/38468155/trumps-stock-loss-means-millions-for-short-sellers-a-lot-of-his-businesses-go-belly-up-quickly">Trump&#8217;s Stock Loss Means Millions For Short Sellers &#8211; &#8216;A Lot Of His Businesses Go Belly Up, Quickly&#8217;</a></em></p>


Politics

Legal

Federal Court To Cannabis Pilot: No More Transporting Weed Around Alaska, FAA Revokes License Though Pot Is Legal There

<h1 class="wp-block-heading"><strong>Top Stories for April 26, 2024:</strong></h1>
<ol>
<li><strong>Anglo American</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAUKF#OTC">AAUKF</a>) rejected the <a href="https://www.benzinga.com/news/large-cap/24/04/38459129/anglo-american-rejects-bhps-highly-unattractive-bid-sets-proposal-deadline-for-may-22">$39-billion all-share takeover</a> bid from <strong>BHP Group</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>), calling it &#8220;highly unattractive&#8221; and undervalued.&nbsp;</li>
</ol>
<p>The offer included conditions like demerging Anglo American's stakes in Amplats and Kumba Iron Ore and Anglo&#8217;s board cited the bid as opportunistic, dilutive to shareholder value and risky.</p>
<p>Despite BHP claiming a 31% premium, Anglo emphasized the proposal underestimated the value of its significant copper holdings.</p>
<p><em>See Also: <a href="https://www.benzinga.com/m-a/24/04/38469869/elliott-managements-1b-anglo-american-stake-ups-ante-as-mining-megamerger-collapses">Elliott Management&#8217;s $1B Anglo American Stake Ups Ante As Mining Megamerger Collapses</a></em></p>
<ol start="2">
<li><strong>Gatos Silver</strong> I<strong>nc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATO#NYSE">GATO</a>) updated on its exploration at the Los Gatos district in Mexico, highlighting new mineral intercepts at the Cerro Los Gatos mine and appointing <strong>Chad Yuhasz</strong> as vice president. </li>
</ol>
<p>CEO <strong>Dale Andres</strong> noted these findings will enhance the next resource estimate due in the third quarter of 2024.&nbsp;</p>
<p>Key intercepts included significant silver, zinc, lead, gold and copper grades.&nbsp;</p>
<p>The company is also preparing for expanded drilling in the second quarter of 2024 and has made progress in Greenfields exploration, with initial results showing potential deeper mineralization.</p>
<p><em>Also Read:</em><a href="https://www.benzinga.com/topic/mining"><em> </em></a><a href="https://www.benzinga.com/news/24/04/38435800/standard-lithium-activates-cutting-edge-plant-paves-way-for-cleaner-mining"><em>Standard Lithium Activates Cutting-Edge Plant, Paves Way For Cleaner Mining</em></a></p>
<ol start="3">
<li><strong>IperionX ADR </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPX#NASDAQ">IPX</a>) successfully installed its commercial-scale HAMR titanium furnace at its new Titanium Manufacturing Campus in Virginia.&nbsp;</li>
</ol>
<p>The furnace offers advantages like lower temperatures, higher efficiencies, shorter cycles and better product quality.&nbsp;</p>
<p>With the campus construction on schedule, the furnace commissioning is set for the second quarter of 2024, and production of titanium powder will start by mid-2024.&nbsp;</p>
<p>IperionX aims to develop a U.S. titanium supply chain using scrap and locally sourced minerals to produce high-performance titanium products more efficiently and with reduced environmental impact.</p>
<ol start="4">
<li><strong>Hycroft Mining</strong> <strong>Holding Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYMC#NASDAQ">HYMC</a>) will be added to the Solactive Global Silver Miners Total Returns Index starting May 1, 2024.&nbsp;</li>
</ol>
<p>Companies eligible for the Silver Index must have significant operations in silver mining, with substantial current or anticipated future revenues from silver mining or closely related activities.</p>
<p>This inclusion recognizes Hycroft&#8217;s significant operations in silver mining and its recent high-grade silver discovery at Hycroft Mine, providing its investors with greater liquidity and trading flexibility.</p>
<p><em>Now Read:</em><a href="https://www.benzinga.com/"><em> </em></a><a href="https://www.benzinga.com/news/24/04/38434933/nigeria-cracks-down-on-dormant-mining-titles-to-stop-license-racketeering"><em>Nigeria Cracks Down On Dormant Mining Titles To Stop &#8216;License Racketeering&#8217;</em></a></p>
<p><strong><em>Benzinga Mining is the bridge between mining companies and retail investors. Reach out to <a href="mailto:licensing@benzinga.com">licensing@benzinga.com</a> to get connected with the Benzinga community!</em></strong><br /></p>
<p><em>Photo: Shutterstock</em></p>


Commodities

Global

AAUKF

GATO

Hycroft Mining Holding Corporation - Class A Common Stock

HYMC

Anglo American Rejects BHP Offer; Gatos Silver's Mineral Findings; IperionX Installs New Furnace And More: Friday's Top Mining Stories

<p><strong>Paul Rosenberg</strong> has been managing rapper Eminem for 27 years. Speaking at the <a href="http://benzinga.com/nfldraft/">Benzinga Sports Business Titans event</a>, Rosenberg shared how he initially met Eminem and the hurdles they overcame together on their path to success.</p>
<p><strong>What Happened:</strong> Today, <a href="http://benzinga.com/topic/eminem">Eminem is one of the most successful</a> musicians on the planet. Without key individuals like Rosenberg and <strong>Dr. Dre,</strong> Eminem may have never succeeded in music.</p>
<p>In a story of perseverance, Rosenberg recalled his first interactions with the musician.</p>
<p>After a semi successful rap career, which included a deal with a local Detroit record label, Rosenberg was ready to go to law school at the age of 22 to become a music lawyer.</p>
<p>"I didn't want to be just a regular lawyer," Rosenberg told the live audience at Benzinga's Detroit headquarters at the Sports Business Titans event.</p>
<p>Rosenberg listened to rap music since he was 11 years old, which blossomed into rapping and later his music law aspirations.</p>
<p>While he was still connected to the local music scene, Rosenberg told musicians that he was going to be a music lawyer and could represent them in the future.</p>
<p>Local retail clothing store The Hip Hop Shop hosted open mics and rap battles that Rosenberg attended.</p>
<p>Detroit rapper <strong>Proof</strong>, who Rosenberg was going to represent as a lawyer, hosted battles and encouraged the future manager to stick around after battles and hear someone he thought was good and happened to be "a white boy."</p>
<p>Rosenberg said he remembers the "audition" like it was yesterday, with Eminem wearing an all-white tracksuit, appearing kinda scrubby looking and kinda pudgy.</p>
<p>"I thought he was really good."</p>
<p>Although, Rosenberg said it wasn't the best thing he had ever seen. Eminem's future manager later bought a $6 cassette from him a month or two later and said it was really good music, well-constructed, but wasn't there in terms of songs and deliveries.</p>
<p>"I'm interested, but I'm not like this is it."</p>
<p>Rosenberg received a call later on from a DJ at The Hip Hop Shop saying that he needed to hear Eminem's new music. That music was the bare bones of what would become "The Slim Shady LP."</p>
<p>"Then I was convinced."</p>
<p><em>Related Link: <a href="https://www.benzinga.com/general/gaming/23/11/35922646/eminem-joins-fortnites-big-bang-event-exclusive-slim-shady-skins-and-a-virtual-concert">Eminem Joins Fortnite&#8217;s Big Bang Event: Exclusive Slim Shady Skins, And A Virtual Concert?</a></em></p>
<p><strong>Lesson In Perseverance</strong>: Rosenberg himself being convinced in Eminem's music wasn't enough to turn the rapper into a success.</p>
<p>Rosenberg said his job was to find Eminem a record deal, but it didn't happen overnight.</p>
<p>"It wasn't a straight path, though. Nobody wanted to sign him," Rosenberg said.</p>
<p>Rosenberg said the landscape for hip hop was very different back then and being a white rapper was not seen as a favorable thing.</p>
<p>"I didn't give up."</p>
<p>Rosenberg said it just took the right someone hearing Eminem and helping him succeed.</p>
<p>"The someone was Dr. Dre."</p>
<p>Dr. Dre heard Eminem freestyle on the radio and also listened to a cassette later and knew it was the same talented musician he heard on the radio, which led to an eventual record deal with Aftermath Entertainment and Interscope Records.</p>
<p>"You shouldn't take no for an answer," Rosenberg said of his perseverance to get Eminem a deal.</p>
<p>Rosenberg said you hear this all the time, but it's so true.</p>
<p>Another important lesson shared with the live Benzinga audience was the 25+ year working relationship between Eminem and Rosenberg.</p>
<p>"I was very lucky that he's a loyal guy. Loyalty's very important."</p>
<p>Rosenberg added that loyalty is less and less valued by people today.</p>
<p>Rosenberg and Eminem were in Detroit for the 2024 NFL Draft, which included a food truck for the Mom's Spaghetti restaurant, which is based on a lyric in the rapper's song "Lose Yourself." The food truck also has official NFL licensed merchandise for sale during the draft in Detroit.</p>
<p>Eminem was one of the featured guests on stage during the 2024 NFL Draft alongside NFL Commissioner <strong>Roger Goodell.</strong></p>
<p>"We know the commissioner now," Rosenberg said. "I call him Rog."</p>
<p>Rosenberg received the "Detroit Inspiration Award" from Benzinga during the Benzinga Sports Business Titans event.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/general/entertainment/23/08/34080360/vivek-ramaswamys-shady-use-of-eminems-rap-draws-rebuke-from-marshall-mathers-himself">Vivek Ramaswamy&#8217;s &#8216;Shady&#8217; Use Of Eminem&#8217;s Rap Draws Rebuke — From Marshall Mathers Himself</a></em></p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Benzinga Sports Business Titans: Unparalleled Athlete Access &amp; Insights Into Success" width="500" height="281" src="https://www.youtube.com/embed/93htkUYdGNc?start=8962&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><em>Photo by Dustin Blitchok.</em></p>


Entertainment

EXCLUSIVE: Eminem's Manager Paul Rosenberg Shares His Story With Multiplatinum Rapper — 'Nobody Wanted To Sign Him, I Didn't Give Up'

<p>Society Pass Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPA#NASDAQ">SOPA</a>) ("SOPA" or the "Company"), Southeast Asia's (SEA) next generation, e-commerce ecosystem, today announced that the board approved a proposed 1-for-15 shares reverse split of its common stock (the "Reverse Split").&nbsp;<br /><br />&nbsp;</p>
<p>Beginning with the opening of trading on&nbsp;May 1, 2024, the Company's common stock will begin trading on a post-Reverse Split basis on the Nasdaq Capital Market under the same symbol "SOPA", but under a new CUSIP number of 83370P201. The objective of the Reverse Split is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market.</p>
<p>Upon the effectiveness of the Reverse Split, every fifteen issued and outstanding shares of common stock with a par value of&nbsp;US$0.0001&nbsp;each will automatically be consolidated into one issued and outstanding common stock with a par value of&nbsp;US$0.0001&nbsp;each. No fractional shares will be issued as a result of the Reverse Split. Instead, any fractional shares that would have resulted from the Reverse Split will be rounded up to the next whole number. The Reverse Split affects all shareholders uniformly and will not alter any shareholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares. The Reverse Split will also reduce the number of authorized shares by the same ratio as the Reverse Split. The Reverse Split was approved by the Company's board of directors. The Company has filed a certificate of change with the Secretary of State of Nevada.</p>


Stock Split

SOPA

Society Pass Incorporated Announces 1-For-15 Reverse Stock Split, Will Begin At The Opening Of Trading On May 1, 2024

WIIM

AMC Entertainment shares are trading higher following a strong preliminary Q1 forecast.

Earnings

IONM

Assure Holdings Says Unaudited Financial Statements For Quarterly Periods Ended March 31 2023, June 30 2023 & Sept 30 2023 Should Not Be Relied Upon; Error Does Not Change Cash Position Of Co At End Of Non-Reliance Periods

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.</p>



<p>I think that investing in robotic surgery stocks is an underrated thematic choice for investors. The reason being is that there is <a href="https://cworldwide.com/insights-news/item/?id=5922&amp;title=advancement-in-robotic-surgery">currently a very low industry penetration</a> of using robots in the surgical market, which means there is potentially money on the table for early investors to take advantage of.</p>



<p>Robotic surgical systems market is <a href="https://www.medicaldevice-network.com/analyst-comment/robotic-surgical-systems-market-displaying-continued-growth/">projected to grow</a> from $3.3 billion in 2023 to $7.2 billion in 2033, with a CAGR of 15.7%. However, barriers include high costs and limited surgeon training, particularly in developing markets.</p>



<p>Still, I firmly believe that robotic surgery stocks is pioneering where the surgical industry is ultimately heading, especially as the average cost of these systems falls and their floorspaces become more efficient.</p>



<p>So here are seven robot surgery stocks for investors to buy in March this year.</p>



<h2>Intuitive Surgical (ISRG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/isrg-stock-300x169.jpg" alt="A sign with the Intuitive Surgical logo standing outside of a company office. ISRG stock."><div>Source: Sundry Photography / Shutterstock.com</div></div><p><strong>Intuitive Surgical</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/isrg-stock-quote/"><strong>ISRG</strong></a></span>) is known for its da Vinci surgical systems, used globally for a variety of procedures.</p>



<p>In Q4 2023, ISRG <a href="https://seekingalpha.com/article/4664538-intuitive-surgical-inc-isrg-q4-2023-earnings-call-transcript">showed strong performance</a> with a 21% increase in da Vinci procedures and a 14% growth in the installed base of systems to 8,606. The full year saw a 9% increase in average system utilization. Revenue for Q4 was $1.93 billion, marking a 17% increase from the previous year, and lLeasing accounted for 48% of Q4 placements.</p>



<p>For 2024, ISRG anticipates a <a href="https://seekingalpha.com/news/4053715-biggest-stock-movers-today-alcon-intuitive-surgical-and-more">13% to 16% increase in procedures</a> compared to 2023, fueled by a 25% rise in U.S. general surgery procedures.</p>



<p>The market seems to be bullish on ISRG&rsquo;s general trajectory as it has a forward P/E ratio of 61 times earnings and analysts rate <a href="https://stockanalysis.com/stocks/isrg/forecast/">the company as a &ldquo;Buy&rdquo;</a>.</p>



<p>Although it may trade at a premium compared with its peer companies, ISRG is the leading brand in robotic surgeries worldwide, and I feel that is expected to continue.</p>



<h2>Stryker (SYK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/syk1600-300x169.jpg" alt="The Stryker (SYK) office in Fremont, California."><div>Source: Sundry Photography / Shutterstock.com</div></div><p><strong>Stryker</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/syk-stock-quote/"><strong>SYK</strong></a></span>) offers the Mako robotic arm, enhancing joint replacement surgery with precision.</p>



<p>The Mako system utilizes a robotic arm to assist surgeons during knee and hip replacement procedures. It provides high precision capabilities by relying on a patient&rsquo;s specific CT scan data to create a 3D model and plan the surgery.</p>



<p>This system seems to be popular, as&nbsp; for FY23, <a href="https://seekingalpha.com/article/4660546-stryker-stock-mako-shoulder-and-spine-launches-are-on-the-way">Stryker forecasted</a> a robust 10.5% organic revenue growth, with further expectations of maintaining a 10% growth rate into FY24.</p>



<p>For Q4 2023, Stryker <a href="https://www.benzinga.com/news/earnings/24/01/36856700/stryker-stock-gains-on-q4-earnings-2024-outlook">reported better-than-expected financial results</a>, with an adjusted earnings per share (<a href="https://investorplace.com/stock-quotes/eps-stock-quote/"><strong>EPS</strong></a>) of $3.46, surpassing the anticipated $3.27, and a revenue of $5.82 billion, exceeding estimates of $5.60 billion.</p>



<p>The company estimates organic net sales growth between 7.5% and 9.0% for 2024, with an adjusted EPS range of $11.70 to $12, and it&rsquo;s perhaps one of the best alternative to ISRG for investors interested in these robotics stocks to buy.</p>



<h2>Becton, Dickinson and Company (BDX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/bdx-stock-1-300x169.jpg" alt="The front of a Becton Dickinson (BDX) office in Ontario, Canada."><div>Source: JHVEPhoto / Shutterstock.com</div></div><p><strong>Becton, Dickinson and Company</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/bdx-stock-quote/"><strong>BDX</strong></a></span>) specializes in medical devices and instrument systems.</p>



<p>One of BDX&rsquo;s key robotic surgery products is the Auriga Robotic Endovascular System. The Auriga system integrates robotics, advanced imaging, and instrumentation to provide precise vascular intervention.</p>



<p>I think that now is a good time for investors to pick up shares of BDX stock. The reason being is that the company <a href="https://seekingalpha.com/news/4061128-becton-dickinson-reports-mixed-q1-results-raises-fy24-outlook">raised its full-year adjusted EPS guidance</a> and the midpoint of organic revenue growth, now expecting fiscal year 2024 revenues to range between approximately $20.2 billion to $20.4 billion.&nbsp;</p>



<p>This is an increase from the previous forecast of $20.1 billion to $20.3 billion. This update includes an expectation for fiscal year 2024 adjusted diluted EPS to be $12.82 to $13.06, adjusted from $12.70 to $13.00 previously&#8203;.</p>



<p>Investing in BDX can be accretive, thanks to the robotics market gradually shifting from a consolidated one to one that&rsquo;s more fractured and decentralized.</p>



<h2>Zimmer Biomet Holdings (ZBH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Zimmer Biomet Holdings</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/zbh-stock-quote/"><strong>ZBH</strong></a></span>) is a leader in medical technology with its ROSA robotics platform. This platform is designed specifically for total knee replacement procedures.</p>



<p>ZBH is another one of those robotics stocks that investors should consider buying, and there could be an attractive entry point to scoop up shares.</p>



<p>The company has initiated a <a href="https://www.marketscreener.com/quote/stock/ZIMMER-BIOMET-HOLDINGS-IN-14996/news/Zimmer-Biomet-forecasts-upbeat-2024-profit-on-steady-medical-devices-demand-45913607/">restructuring program</a> aimed at cutting costs, expecting run-rate savings of about $200 million by 2025. ZBH also anticipates full-year 2024 profit in the range of $8-$8.15 per share, surpassing analysts&rsquo; expectations of $7.95. Moreover, ZBH projects its full-year revenue to grow between 5% to 6% on a constant currency basis.</p>



<p>I think that ZBH is one of the cheaper robotics stocks for investors to buy. Its forward P/E is just 15 times earnings, and analysts gave it a &ldquo;Hold&rdquo; rating. However, I think that some caution is being given amid ZBH&rsquo;s restructuring, and this is giving it a discount to its intrinsic value, which could be higher than its share price reflects.</p>



<h2>Smith &amp; Nephew (SNN)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/04/snnmsn-300x165.jpg" alt="Smith &amp; Nephew plc (ADR) (SNN)"><div>Source: Shutterstock</div></div><p><strong>Smith &amp; Nephew</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/snn-stock-quote/"><strong>SNN</strong></a></span>) focuses on orthopedic reconstruction and sports medicine.</p>



<p>In the orthopedic robotics arena, Smith &amp; Nephew has partnered with <strong>Brainlab</strong> to co-market the ROBOTICS KNEE platform for total knee replacement procedures. Key features include robotic control during the bone cutting process, integrated navigation software, and patient-specific 3D planning based on medical imaging.</p>



<p>Looking ahead, SNN expects an <a href="https://www.marketscreener.com/quote/stock/SMITH-NEPHEW-PLC-9590181/news/Smith-Nephew-plc-Provides-Earnings-Guidance-for-2024-46058224/">underlying revenue growth</a> in the range of 5% to 6% (4.6% to 5.6% reported) and targeting a trading profit margin of at least 18%.</p>



<p>As a smaller company with a market cap of just 12 billion, SNN <a href="https://stockanalysis.com/stocks/snn/forecast/">could be accretive</a> for investors who buy shares while the company is still in its infancy. The newness of the business has also led some analysts to set bullish projections for the firm.&nbsp;</p>



<p>One analyst expects SNN&rsquo;s EPS to increase 71.22% this year, rising to 1.03. There is also a slight upside for its stock price at the time of writing.</p>



<h2>Globus Medical (GMED)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/medical-bills-1600-300x169.png" alt="Doctor or physician calculating a patients medical bills at a desk. Medical bills, health costs, health expenses."><div>Source: THICHA SATAPITANON / Shutterstock</div></div><p><strong>Globus Medical </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/gmed-stock-quote/"><strong>GMED</strong></a></span>) is known for its innovation in musculoskeletal solutions. Meanwhile, in the robotic surgery market, GMED has the ExcelsiusGPS robotic navigation platform for spine procedures. Key applications include robotic trajectory guidance for pedicle screw placement during spine surgeries like fusions, decompressions, etc.</p>



<p>GMED <a href="https://finance.yahoo.com/news/globus-medical-inc-gmed-posts-215407157.html">reported significant financial achievements in 2023</a>, including record worldwide net sales of $616.5 million in Q4 and $1.568 billion for the full year. This growth was largely driven by its merger with<strong> NuVasive </strong>and increased product volumes. Meanwhile, non-GAAP net income rose by 38.9%, and the company reaffirmed its full-year 2024 revenue guidance range of $2.450 billion to $2.475 billion, with non-GAAP EPS between $2.68 to $2.7.</p>



<p>The company also expects to achieve $170 million in synergies from the NuVasive merger over the next three years, and is one of the key reasons that I feel investors should consider buying GMED stock over the long-run.</p>



<h2>Medtronic (MDT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mdt-stock-1-300x169.jpg" alt="Medtronic (MDT) sign outside office building representing healthcare stocks"><div>Source: JHVEPhoto / Shutterstock.com</div></div><p><strong>Medtronic</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/mdt-stock-quote/"><strong>MDT</strong></a></span>) is a leader in medical technology, offering the Hugo robotic-assisted surgery system. Medtronic offers the Hugo robotic-assisted surgery system through its acquisition of <strong>Mazor Robotics</strong> in 2018.</p>



<p>Key features of Hugo include its modular design for efficient setup, its slimmer profile compared to other systems, and its ability to be utilized in hybrid operating rooms. While later to market than pioneering systems like ISGR&rsquo;s, Hugo aims to bring robotic precision to commonly performed procedures like spine surgeries first.</p>



<p>Medtronic has raised its <a href="https://www.bizjournals.com/twincities/news/2023/08/22/medtronic-q1-fiscal-2024-outlook.html">financial outlook</a> for the upcoming year following better-than-expected sales and earnings in the first quarter of fiscal 2024. The company now expects its full-year earnings to be between $5.08 and $5.16 per share, an increase from the previously projected range of $5 to $5.10 per share.</p>



<p>Therefore, now could be a good time for investors to scoop up shares of MDT, with each of its four segments delivering 6% organic revenue growth so far in 2024.</p>



<p><em>On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> </em>InvestorPlace.com Publishing Guidelines</a>.</p>
<div><p>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/7-robotic-surgery-stocks-to-buy-for-the-future-of-healthcare/">7 Robotic Surgery Stocks to Buy for the Future of Healthcare</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Robotic Surgery Stocks to Buy for the Future of Healthcare

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>There are some robotic surgery stocks for investors to buy in March this year. The growth of robotic-assisted surgery has been driven by its potential benefits, such as smaller incisions, reduced pain and scarring, quicker recovery times, and improved clinical outcomes.</p>



<p>I think that investing in robotic surgery stocks is an underrated thematic choice for investors. The reason being is that there is <a href="https://cworldwide.com/insights-news/item/?id=5922&amp;title=advancement-in-robotic-surgery">currently a very low industry penetration</a> of using robots in the surgical market, which means there is potentially money on the table for early investors to take advantage of.</p>



<p>Robotic surgical systems market is <a href="https://www.medicaldevice-network.com/analyst-comment/robotic-surgical-systems-market-displaying-continued-growth/">projected to grow</a> from $3.3 billion in 2023 to $7.2 billion in 2033, with a CAGR of 15.7%. However, barriers include high costs and limited surgeon training, particularly in developing markets.</p>



<p>Still, I firmly believe that robotic surgery stocks is pioneering where the surgical industry is ultimately heading, especially as the average cost of these systems falls and their floorspaces become more efficient.</p>



<p>So here are seven robot surgery stocks for investors to buy in March this year.</p>



<h2>Intuitive Surgical (ISRG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/isrg-stock-300x169.jpg" alt="A sign with the Intuitive Surgical logo standing outside of a company office. ISRG stock."><div>Source: Sundry Photography / Shutterstock.com</div></div><p><strong>Intuitive Surgical</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/isrg-stock-quote/"><strong>ISRG</strong></a></span>) is known for its da Vinci surgical systems, used globally for a variety of procedures.</p>



<p>In Q4 2023, ISRG <a href="https://seekingalpha.com/article/4664538-intuitive-surgical-inc-isrg-q4-2023-earnings-call-transcript">showed strong performance</a> with a 21% increase in da Vinci procedures and a 14% growth in the installed base of systems to 8,606. The full year saw a 9% increase in average system utilization. Revenue for Q4 was $1.93 billion, marking a 17% increase from the previous year, and lLeasing accounted for 48% of Q4 placements.</p>



<p>For 2024, ISRG anticipates a <a href="https://seekingalpha.com/news/4053715-biggest-stock-movers-today-alcon-intuitive-surgical-and-more">13% to 16% increase in procedures</a> compared to 2023, fueled by a 25% rise in U.S. general surgery procedures.</p>



<p>The market seems to be bullish on ISRG&rsquo;s general trajectory as it has a forward P/E ratio of 61 times earnings and analysts rate <a href="https://stockanalysis.com/stocks/isrg/forecast/">the company as a &ldquo;Buy&rdquo;</a>.</p>



<p>Although it may trade at a premium compared with its peer companies, ISRG is the leading brand in robotic surgeries worldwide, and I feel that is expected to continue.</p>



<h2>Stryker (SYK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/syk1600-300x169.jpg" alt="The Stryker (SYK) office in Fremont, California."><div>Source: Sundry Photography / Shutterstock.com</div></div><p><strong>Stryker</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/syk-stock-quote/"><strong>SYK</strong></a></span>) offers the Mako robotic arm, enhancing joint replacement surgery with precision.</p>



<p>The Mako system utilizes a robotic arm to assist surgeons during knee and hip replacement procedures. It provides high precision capabilities by relying on a patient&rsquo;s specific CT scan data to create a 3D model and plan the surgery.</p>



<p>This system seems to be popular, as&nbsp; for FY23, <a href="https://seekingalpha.com/article/4660546-stryker-stock-mako-shoulder-and-spine-launches-are-on-the-way">Stryker forecasted</a> a robust 10.5% organic revenue growth, with further expectations of maintaining a 10% growth rate into FY24.</p>



<p>For Q4 2023, Stryker <a href="https://www.benzinga.com/news/earnings/24/01/36856700/stryker-stock-gains-on-q4-earnings-2024-outlook">reported better-than-expected financial results</a>, with an adjusted earnings per share (<a href="https://investorplace.com/stock-quotes/eps-stock-quote/"><strong>EPS</strong></a>) of $3.46, surpassing the anticipated $3.27, and a revenue of $5.82 billion, exceeding estimates of $5.60 billion.</p>



<p>The company estimates organic net sales growth between 7.5% and 9.0% for 2024, with an adjusted EPS range of $11.70 to $12, and it&rsquo;s perhaps one of the best alternative to ISRG for investors interested in these robotics stocks to buy.</p>



<h2>Becton, Dickinson and Company (BDX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/bdx-stock-1-300x169.jpg" alt="The front of a Becton Dickinson (BDX) office in Ontario, Canada."><div>Source: JHVEPhoto / Shutterstock.com</div></div><p><strong>Becton, Dickinson and Company</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/bdx-stock-quote/"><strong>BDX</strong></a></span>) specializes in medical devices and instrument systems.</p>



<p>One of BDX&rsquo;s key robotic surgery products is the Auriga Robotic Endovascular System. The Auriga system integrates robotics, advanced imaging, and instrumentation to provide precise vascular intervention.</p>



<p>I think that now is a good time for investors to pick up shares of BDX stock. The reason being is that the company <a href="https://seekingalpha.com/news/4061128-becton-dickinson-reports-mixed-q1-results-raises-fy24-outlook">raised its full-year adjusted EPS guidance</a> and the midpoint of organic revenue growth, now expecting fiscal year 2024 revenues to range between approximately $20.2 billion to $20.4 billion.&nbsp;</p>



<p>This is an increase from the previous forecast of $20.1 billion to $20.3 billion. This update includes an expectation for fiscal year 2024 adjusted diluted EPS to be $12.82 to $13.06, adjusted from $12.70 to $13.00 previously&#8203;.</p>



<p>Investing in BDX can be accretive, thanks to the robotics market gradually shifting from a consolidated one to one that&rsquo;s more fractured and decentralized.</p>



<h2>Zimmer Biomet Holdings (ZBH)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Zimmer Biomet Holdings</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/zbh-stock-quote/"><strong>ZBH</strong></a></span>) is a leader in medical technology with its ROSA robotics platform. This platform is designed specifically for total knee replacement procedures.</p>



<p>ZBH is another one of those robotics stocks that investors should consider buying, and there could be an attractive entry point to scoop up shares.</p>



<p>The company has initiated a <a href="https://www.marketscreener.com/quote/stock/ZIMMER-BIOMET-HOLDINGS-IN-14996/news/Zimmer-Biomet-forecasts-upbeat-2024-profit-on-steady-medical-devices-demand-45913607/">restructuring program</a> aimed at cutting costs, expecting run-rate savings of about $200 million by 2025. ZBH also anticipates full-year 2024 profit in the range of $8-$8.15 per share, surpassing analysts&rsquo; expectations of $7.95. Moreover, ZBH projects its full-year revenue to grow between 5% to 6% on a constant currency basis.</p>



<p>I think that ZBH is one of the cheaper robotics stocks for investors to buy. Its forward P/E is just 15 times earnings, and analysts gave it a &ldquo;Hold&rdquo; rating. However, I think that some caution is being given amid ZBH&rsquo;s restructuring, and this is giving it a discount to its intrinsic value, which could be higher than its share price reflects.</p>



<h2>Smith &amp; Nephew (SNN)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/04/snnmsn-300x165.jpg" alt="Smith &amp; Nephew plc (ADR) (SNN)"><div>Source: Shutterstock</div></div><p><strong>Smith &amp; Nephew</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/snn-stock-quote/"><strong>SNN</strong></a></span>) focuses on orthopedic reconstruction and sports medicine.</p>



<p>In the orthopedic robotics arena, Smith &amp; Nephew has partnered with <strong>Brainlab</strong> to co-market the ROBOTICS KNEE platform for total knee replacement procedures. Key features include robotic control during the bone cutting process, integrated navigation software, and patient-specific 3D planning based on medical imaging.</p>



<p>Looking ahead, SNN expects an <a href="https://www.marketscreener.com/quote/stock/SMITH-NEPHEW-PLC-9590181/news/Smith-Nephew-plc-Provides-Earnings-Guidance-for-2024-46058224/">underlying revenue growth</a> in the range of 5% to 6% (4.6% to 5.6% reported) and targeting a trading profit margin of at least 18%.</p>



<p>As a smaller company with a market cap of just 12 billion, SNN <a href="https://stockanalysis.com/stocks/snn/forecast/">could be accretive</a> for investors who buy shares while the company is still in its infancy. The newness of the business has also led some analysts to set bullish projections for the firm.&nbsp;</p>



<p>One analyst expects SNN&rsquo;s EPS to increase 71.22% this year, rising to 1.03. There is also a slight upside for its stock price at the time of writing.</p>



<h2>Globus Medical (GMED)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/medical-bills-1600-300x169.png" alt="Doctor or physician calculating a patients medical bills at a desk. Medical bills, health costs, health expenses."><div>Source: THICHA SATAPITANON / Shutterstock</div></div><p><strong>Globus Medical </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/gmed-stock-quote/"><strong>GMED</strong></a></span>) is known for its innovation in musculoskeletal solutions. Meanwhile, in the robotic surgery market, GMED has the ExcelsiusGPS robotic navigation platform for spine procedures. Key applications include robotic trajectory guidance for pedicle screw placement during spine surgeries like fusions, decompressions, etc.</p>



<p>GMED <a href="https://finance.yahoo.com/news/globus-medical-inc-gmed-posts-215407157.html">reported significant financial achievements in 2023</a>, including record worldwide net sales of $616.5 million in Q4 and $1.568 billion for the full year. This growth was largely driven by its merger with<strong> NuVasive </strong>and increased product volumes. Meanwhile, non-GAAP net income rose by 38.9%, and the company reaffirmed its full-year 2024 revenue guidance range of $2.450 billion to $2.475 billion, with non-GAAP EPS between $2.68 to $2.7.</p>



<p>The company also expects to achieve $170 million in synergies from the NuVasive merger over the next three years, and is one of the key reasons that I feel investors should consider buying GMED stock over the long-run.</p>



<h2>Medtronic (MDT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/mdt-stock-1-300x169.jpg" alt="Medtronic (MDT) sign outside office building representing healthcare stocks"><div>Source: JHVEPhoto / Shutterstock.com</div></div><p><strong>Medtronic</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/mdt-stock-quote/"><strong>MDT</strong></a></span>) is a leader in medical technology, offering the Hugo robotic-assisted surgery system. Medtronic offers the Hugo robotic-assisted surgery system through its acquisition of <strong>Mazor Robotics</strong> in 2018.</p>



<p>Key features of Hugo include its modular design for efficient setup, its slimmer profile compared to other systems, and its ability to be utilized in hybrid operating rooms. While later to market than pioneering systems like ISGR&rsquo;s, Hugo aims to bring robotic precision to commonly performed procedures like spine surgeries first.</p>



<p>Medtronic has raised its <a href="https://www.bizjournals.com/twincities/news/2023/08/22/medtronic-q1-fiscal-2024-outlook.html">financial outlook</a> for the upcoming year following better-than-expected sales and earnings in the first quarter of fiscal 2024. The company now expects its full-year earnings to be between $5.08 and $5.16 per share, an increase from the previously projected range of $5 to $5.10 per share.</p>



<p>Therefore, now could be a good time for investors to scoop up shares of MDT, with each of its four segments delivering 6% organic revenue growth so far in 2024.</p>



<p><em>On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> </em>InvestorPlace.com Publishing Guidelines</a>.</p>
<div><p>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/7-robotic-surgery-stocks-to-buy-for-the-future-of-healthcare/">7 Robotic Surgery Stocks to Buy for the Future of Healthcare</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on HCA Healthcare (HCA – Research Report), Eli Lilly & ...

Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Eli Lilly & Co (LLY) and Globus Medical (GMED)

Globus Medical Inc (GMED) receives a strong  valuation score of 70 from InvestorsObserver analysis. Our proprietary scoring system considers the overall health of the company by looking at the stock's price, earnings, and growth rate to determine if it represents a good value. GMED holds a better value than 70% of stocks a

Globus Medical Inc (GMED) Stock: How Does it Score on Fundamental Metrics?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of the riskier but incredibly compelling opportunities, robotics stocks could be poised to mint new millionaires. It all comes down to the projected numbers.</p>



<p>According to Precedence Research, the global robotics technology market reached an <a href="https://www.precedenceresearch.com/robotics-technology-market">estimated valuation of $72.17 billion in 2022</a>. Further, experts believe that the segment could expand to $283.19 billion by 2032, implying a compound annual growth rate (CAGR) of 14.7%. That&rsquo;s impressive. And that could also be understated.</p>



<p>Basically, robotics encompasses multiple fields. Yes, the invention implies industrial use and that&rsquo;s probably where the innovation will be most concentrated. However, robotics intertwine with advancements in artificial intelligence, machine learning and other intelligent solutions.</p>



<p>Stated differently, the machines could soon be everywhere. On that note, below are enticing robotics stocks to consider.</p>



<h2>Columbus McKinnon (CMCO)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/06/robotics-stocks-1600-300x169.jpg" alt="a worker with a tablet remotely operates a standalone robot arm. Get Rich with Robotics. Best Robotics Stocks to Buy. favorite robotics stocks"><div>Source: Shutterstock</div></div><p>Listed under the industrials sector &ndash; specifically the farm and heavy construction machinery subsegment &ndash; <strong>Columbus McKinnon</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmco-stock-quote/"><strong>CMCO</strong></a>) designs, manufactures and markets intelligent motion solutions for moving, lifting, positioning and securing materials worldwide. Per its <a href="https://finance.yahoo.com/quote/CMCO/profile">public profile</a>, it offers hoists, winches, hydraulic jacks and other industrial equipment.</p>



<p>It&rsquo;s one of the lesser-appreciated robotics stocks thanks to its advancements in automotive automation. This innovative approach involves the use of <a href="https://www.cmco.com/en-us/industries/automotive/automation/">computer-programmed mechanical equipment</a> during the assembly of a vehicle. Notably, Grand View Research states that the underlying global industrial automation and control systems market size <a href="https://www.grandviewresearch.com/industry-analysis/industrial-automation-market">could expand to $377.25 billion by 2030</a>.</p>



<p>Last fiscal year, Columbus consistently posted positive adjusted earnings. Overall, the average positive surprise during the last four quarters came out to 6.4%. For fiscal 2024, analysts anticipate earnings per share of $2.95 on revenue of $1.02 billion. In 2023, the company posted EPS of $2.94 on sales of $936.24 million.</p>



<p>Lastly, D.A. Davidson rates CMCO a &ldquo;buy&rdquo; with a <a href="https://www.tipranks.com/stocks/cmco/forecast">$50 price target</a>, implying 17% upside over the next 12 months.</p>



<h2>Globus Medical (GMED)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/robotics-medical-1600-300x169.jpg" alt="robotic arms over medical bed symbolizing medical robotics. favorite robotics stocks"><div>Source: shutterstock.com/MAD.vertise</div></div><p>Falling under the healthcare category, <strong>Globus Medical</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/gmed-stock-quote/"><strong>GMED</strong></a>) is involved in medical devices. Specifically, it develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Per its <a href="https://finance.yahoo.com/quote/gmed/profile">corporate profile</a>, Globus offers spine products, such as traditional fusion implants comprising multiple components. It also offers corpectomy devices for treating degenerative and congenital conditions, deformity, tumors and trauma injuries.</p>



<p>GMED makes the cut for robotics stocks thanks to its revolutionary robotic navigation platform, the world&rsquo;s first. This innovation combines a rigid robotic arm and full navigation capabilities into one adaptable platform for accurate alignment in spine surgery. Notably, MarketsandMarkets believes that the sector <a href="https://www.marketsandmarkets.com/Market-Reports/medical-robotic-systems-market-2916860.html#:~:text=The%20global%20medical%20robots%20market,trend%20analysis%20of%20the%20market.">could be poised to reach $33.8 billion by 2029</a>.</p>



<p>For the current fiscal year, analysts believe that Globus will post EPS of $2.69 on revenue of $2.46 billion. Last year, the company posted EPS of $2.32 on sales of $1.57 billion. That&rsquo;s a 57.1% implied sales upside.</p>



<p>Covering experts peg shares a <a href="https://www.tipranks.com/stocks/gmed/forecast">moderate buy with a $65.90</a> price target, projecting over 26% growth potential. The high-side target lands at an ambitious $83.</p>



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/08/kscp1600-300x169.png" alt="Knightscope (KSCP) security robot patrols an outdoor parking lot"><div>Source: Michael Vi / Shutterstock.com</div></div><p>If you really want robotics stocks that could mint millionaires as quickly as possible, <strong>Knightscope</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/"><strong>KSCP</strong></a>) could be the idea for you. Listed under the industrials category, Knightscope operates under the security and protection services subsegment. The designs, develops, manufactures, markets, deploys and supports autonomous security robots (ASRs) in the U.S.</p>



<p>It&rsquo;s not quite Robocop. However, it&rsquo;s not too far off in terms of providing basic automated security. Here&rsquo;s the situation. Right now, lots of folks <a href="https://www.wsj.com/articles/police-departments-are-losing-officers-and-struggling-to-replace-them-11643288401">don&rsquo;t want careers in law enforcement</a> due to the dangers and public scrutiny. Plus, police officers can&rsquo;t be everywhere patrolling every nook and cranny. That&rsquo;s where automated security robots could help act as a force multiplier.</p>



<p>The thing about Knightscope is that it&rsquo;s an extremely risky idea. Yes, it could fly higher but it could also crash and burn. Over the past five years, KSCP stock lost 97% of equity value.</p>



<p>At the same time, <a href="https://www.businesswire.com/news/home/20240104703804/en/Ascendiant-Capital-Markets-Maintains-Buy-Rating-for-Knightscope-Raises-Per-Share-Price-Target-to-4.00">Ascendiant rates KSCP a &ldquo;buy&rdquo; with a $4 price target</a>. That implies upside potential of 749%. If you want to gamble with robotics stocks, this might be the name that could skyrocket higher.</p>



<p><strong><a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a></strong></p>



<p><strong><em>On Penny Stocks and Low-Volume Stocks:</em></strong><em>&nbsp;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&nbsp;<a href="http://investorplace.com/">InvestorPlace.com</a>&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em>Read More:&nbsp;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/03/from-six-figures-to-seven-3-robotics-stocks-set-to-make-millionaires/">From Six Figures to Seven: 3 Robotics Stocks Set to Make Millionaires</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

From Six Figures to Seven: 3 Robotics Stocks Set to Make Millionaires

Don't expect pandemic backlog to fuel orthopedic sales, says Needham

In a report released on April 15, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Globus Medical (GMED – Research Report), with a p...

RBC Capital Sticks to Its Buy Rating for Globus Medical (GMED)

Analysts fell to the sidelines weighing in on Gilead Sciences (GILD – Research Report), Globus Medical (GMED – Research Report) and Merck & Company...